Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2005 1
2011 1
2012 1
2018 3
2020 1
2021 3
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Pediatric neurofibromatosis of the larynx: report ofatypical location.
Varela-Goodall N, Acosta MB, Scatolini ML, Cocciaglia A. Varela-Goodall N, et al. Among authors: acosta mb. Arch Argent Pediatr. 2023 Jun 1;121(3):e202202782. doi: 10.5546/aap.2022-02782.eng. Epub 2023 Jan 26. Arch Argent Pediatr. 2023. PMID: 36692429 Free article. English, Spanish.
Exploring the Relationship Between Self-Isolation and Distress Among People with Gastrointestinal Disorders During the COVID-19 Pandemic.
Mikocka-Walus A, Skvarc D, de Acosta MB, Evertsz FB, Bernstein CN, Burisch J, Ferreira N, Gearry RB, Graff LA, Jedel S, Mokrowiecka A, Stengel A, Trindade IA, van Tilburg MAL, Knowles SR. Mikocka-Walus A, et al. Among authors: de acosta mb. J Clin Psychol Med Settings. 2022 Sep;29(3):654-665. doi: 10.1007/s10880-021-09818-9. Epub 2021 Sep 7. J Clin Psychol Med Settings. 2022. PMID: 34494184 Free PMC article.
Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.
Marín-Jiménez I, Acosta MB, Esteve M, Castro-Laria L, García-López S, Ceballos D, Echarri A, Martín-Arranz MD, Busquets D, Llaó J, Navarro-Llavat M, Huguet JM, Argüelles-Arias F, Vicente R, Boudet JM, Díaz G, Sánchez-Migallón AM, Casellas F; for RAPIDA trial investigators. Marín-Jiménez I, et al. Among authors: acosta mb. Gastroenterol Hepatol. 2022 Mar;45(3):165-176. doi: 10.1016/j.gastrohep.2021.04.010. Epub 2021 May 27. Gastroenterol Hepatol. 2022. PMID: 34051313 Clinical Trial. English, Spanish.
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involved.
Guijarro LG, Cano-Martínez D, Toledo-Lobo MV, Salinas PS, Chaparro M, Gómez-Lahoz AM, Zoullas S, Rodríguez-Torres R, Román ID, Monasor LS, Ruiz-Llorente L, Del Carmen Boyano-Adánez M, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Acosta MB, Vera I, Martín-Arranz MD, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Alvarez-Mon M, Gisbert JP, Ortega MA, Hernández-Breijo B, On Behalf Of The Predicrohn Study Group From Geteccu. Guijarro LG, et al. Among authors: acosta mb. Biomed Pharmacother. 2021 Dec;144:112239. doi: 10.1016/j.biopha.2021.112239. Epub 2021 Sep 30. Biomed Pharmacother. 2021. PMID: 34601192 Free article.
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group. Chaparro M, et al. Among authors: de acosta mb. Aliment Pharmacol Ther. 2018 Oct;48(8):839-851. doi: 10.1111/apt.14930. Aliment Pharmacol Ther. 2018. PMID: 30281832
IMPACT OF MESALAZINE ON THE RESPONSE TO COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. RESULTS OF A PROSPECTIVE MULTICENTRE STUDY OF GETECCU (VACOVEII STUDY).
Deza DC, Julián Gomara AB, Biota EC, Beltrán B, Domènech E, Casbas AG, Mañosa M, Zabana Y, Alfaro LR, Romero EV, González EG, Sicilia B, Laredo V, Alcalá Escriche MJ, Velázquez LM, Iglesias RF, Pérez AP, Calafat M, Iturria SR, Yudego IM, Nieto YB, Mateo SG, Gisbert JP, Lidón RV, Arias L, Alfambra E, Roche PC, de Acosta MB, López SG. Deza DC, et al. Among authors: de acosta mb. Gastroenterol Hepatol. 2024 Jan 12:S0210-5705(24)00017-7. doi: 10.1016/j.gastrohep.2023.12.012. Online ahead of print. Gastroenterol Hepatol. 2024. PMID: 38219960 English, Spanish.
13 results